99Tc-MDP Treatment for Knee Osteoarthritis
Recruiting · NCT02993029 · Interventional (participants receive a specific treatment) · Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
View the official record on ClinicalTrials.gov →Interventions studied
99Tc-MDPCelecoxib
What this trial is about
Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.
Who can take part
Age range
40 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants with painful osteoarthritis;
- The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;
- Participants voluntarily participate in the trial, and signed the informed consent.
Exclusion criteria
- Knee joint replacement;
- Inflammatory arthritis or joint infection of knee;
- Nervous joint disease;
- Fracture of joint;
- Gout arthritis of the knee;
- Traumatic arthritis.
Where it is running
1 location listed.
- Department of Nuclear Medicine, Tenth People's Hospital of Tongji University - Shanghai, Shanghai Municipality, China